Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, can neutralize the virus. It is, however, unknown which features of the serological response may affect clinical outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Röltgen, Katharina, Powell, Abigail E., Wirz, Oliver F., Stevens, Bryan A., Hogan, Catherine A., Najeeb, Javaria, Hunter, Molly, Wang, Hannah, Sahoo, Malaya K., Huang, ChunHong, Yamamoto, Fumiko, Manohar, Monali, Manalac, Justin, Otrelo-Cardoso, Ana R., Pham, Tho D., Rustagi, Arjun, Rogers, Angela J., Shah, Nigam H., Blish, Catherine A., Cochran, Jennifer R., Jardetzky, Theodore S., Zehnder, James L., Wang, Taia T., Narasimhan, Balasubramanian, Gombar, Saurabh, Tibshirani, Robert, Nadeau, Kari C., Kim, Peter S., Pinsky, Benjamin A., Boyd, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857392/
https://www.ncbi.nlm.nih.gov/pubmed/33288645
http://dx.doi.org/10.1126/sciimmunol.abe0240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857392/
https://www.ncbi.nlm.nih.gov/pubmed/33288645
http://dx.doi.org/10.1126/sciimmunol.abe0240

Ejemplares similares